Cargando…

Clinical Utility of β(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

This nonsystematic review provides a summary of current evidence on the use of β(3)-adrenoreceptor agonists (β(3)-ARAs) for the treatment for lower urinary tract symptoms. Soon after their discovery in 1989, β(3)-ARs were identified as a predominant adrenoreceptor subtype in the human urinary bladde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krhut, Jan, Skugarevská, Barbora, Míka, David, Lund, Lars, Zvara, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056051/ https://www.ncbi.nlm.nih.gov/pubmed/35502186 http://dx.doi.org/10.2147/RRU.S309144

Ejemplares similares

Peroneal Electric Transcutaneous NeuroModulation (eTNM(®)): A Novel Method for the Treatment of the Overactive Bladder
por: Krhut, Jan, et al.
Publicado: (2021)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2018)

The use of β(2)-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines
por: Nino, Gustavo, et al.
Publicado: (2020)

Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
por: Roig, Jorge, et al.
Publicado: (2009)

Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy
por: Yang, Chongzhe, et al.
Publicado: (2022)

β-Adrenoreceptor agonists in the management of pain associated with renal colic: a systematic review
por: Tabner, Andrew John, et al.
Publicado: (2016)

Current pharmacotherapy of overactive bladder
por: Kreydin, Evgenyi I., et al.
Publicado: (2021)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
por: Kwon, Se Yun, et al.
Publicado: (2020)

Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord
por: Zvara, Peter, et al.
Publicado: (2007)

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2020)

Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives
por: Janssen, Dick AW, et al.
Publicado: (2017)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently
por: Chan, Chao-Shun, et al.
Publicado: (2022)

MRI Assessment of Cardiomyopathy Induced by β1-Adrenoreceptor Autoantibodies and Protection Through β3-Adrenoreceptor Overexpression
por: Vanhoutte, Laetitia, et al.
Publicado: (2017)

Efficacy of mirabegron, a β(3)‐adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post‐hoc analysis of pooled data from two randomized, placebo‐controlled, double‐blind studies
por: Takahashi, Satoru, et al.
Publicado: (2021)

Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder
por: Igawa, Yasuhiko, et al.
Publicado: (2010)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Inhalation of a Short-Acting β(2)-Adrenoreceptor Agonist Induces a Hypercoagulable State in Healthy Subjects
por: Ali-Saleh, Mais, et al.
Publicado: (2016)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Current Therapies and New Targets to Fight Melanoma: A Promising Role for the β3-Adrenoreceptor
por: Filippi, Luca, et al.
Publicado: (2020)

Comparative In Vitro Study of Various α(2)-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal
por: Porta Bonete, Guillaume, et al.
Publicado: (2020)

Social, economic, and health utility considerations in the treatment of overactive bladder
por: Sacco, Emilio, et al.
Publicado: (2010)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

Spotlight on ROS and β3-Adrenoreceptors Fighting in Cancer Cells
por: Calvani, Maura, et al.
Publicado: (2019)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

ß-Adrenoreceptors in Human Cancers
por: Kraboth, Zoltan, et al.
Publicado: (2023)

The effects of novel α(2)-adrenoreceptor agonist dexmedetomidine on shivering in patients underwent caesarean section
por: Yu, Gaofeng, et al.
Publicado: (2019)

Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches
por: Osman, Nadir I., et al.
Publicado: (2013)

Sacral neuromodulation in overactive bladder: a review and current perspectives
por: Sukhu, Troy, et al.
Publicado: (2016)

β-Adrenoreceptor Stimulation Mediates Reconsolidation of Social Reward-Related Memories
por: Achterberg, E. J. Marijke, et al.
Publicado: (2012)

Src activation by β-adrenoreceptors is a key switch for tumor metastasis
por: Armaiz-Pena, Guillermo N., et al.
Publicado: (2013)

Polymorphisms of β1-Adrenoreceptor Gene and Cardiovascular Complications in Patients with Thyrotoxicosis
por: Babenko, A. Y., et al.
Publicado: (2014)

β3-Adrenoreceptors as ROS Balancer in Hematopoietic Stem Cell Transplantation
por: Pasha, Amada, et al.
Publicado: (2021)

Astrocytes, Noradrenaline, α1-Adrenoreceptors, and Neuromodulation: Evidence and Unanswered Questions
por: Wahis, Jérôme, et al.
Publicado: (2021)

The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro
por: Anderson, Ronald, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jiv5h5cjfc7m8gulm6rd64hbd2